Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technol... Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0031 | 31 | 0.01 | 0.015 | 0.01 | 6306 | 0.01304748 | CS |
| 4 | 0.0004 | 3.14960629921 | 0.0127 | 0.015 | 0.01 | 4205 | 0.01286547 | CS |
| 12 | 0.0001 | 0.769230769231 | 0.013 | 0.017 | 0.01 | 5562 | 0.01281808 | CS |
| 26 | 0.001 | 8.26446280992 | 0.0121 | 0.02445 | 0.01 | 5193 | 0.01267102 | CS |
| 52 | -0.0364 | -73.5353535354 | 0.0495 | 0.074 | 0.0002 | 42524 | 0.04163335 | CS |
| 156 | -0.0481 | -78.5947712418 | 0.0612 | 0.1 | 0.0002 | 52931 | 0.04656987 | CS |
| 260 | -0.0481 | -78.5947712418 | 0.0612 | 0.1 | 0.0002 | 52931 | 0.04656987 | CS |
frans
11月前
shurtha2000
11月前
NRS
11月前
USVIHI22
11月前
USVIHI22
11月前
USVIHI22
11月前
USVIHI22
1年前
USVIHI22
1年前
USVIHI22
1年前
frans
1年前
Muhbruh
1年前
Muhbruh
1年前
RedKnight1
1年前
USVIHI22
1年前
Invest-in-America
1年前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。